Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Materia Medica Bioengineering Institute is a biotechnology company and research entity closely associated with the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences. The institute focuses on the research, development, and industrialization of innovative drugs, particularly in the fields of bioengineering and natural product synthesis. It provides a bridge between academic research and commercial drug production, offering services in drug screening, process optimization, and pilot-scale manufacturing. Its portfolio typically includes projects related to anti-infectives, oncology, and metabolic disorders, leveraging the extensive chemical and biological resources of its parent network.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Materia Medica Bioengineering Institute.